Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry

Jesse Alt, Michelle C. Potter, Camilo Rojas, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

Glutamine is an abundant amino acid that plays pivotal roles in cell growth, cell metabolism, and neurotransmission. Dysregulation of glutamine-using pathways has been associated with pathological conditions such as cancer and neurodegenerative diseases. 6-Diazo-5-oxo-l-norleucine (DON) is a reactive glutamine analog that inhibits enzymes affecting glutamine metabolism such as glutaminase, 2-N-amidotransferase, l-asparaginase, and several enzymes involved in pyrimidine and purine de novo synthesis. As a result, DON is actively used in preclinical models of cancer and neurodegenerative disease. Moreover, there have been several clinical trials using DON to treat a variety of cancers. Considerations of dose and exposure are especially important with DON treatment due to its narrow therapeutic window and significant side effects. Consequently, a robust quantification bioassay is of interest. DON is a polar unstable molecule that has made quantification challenging. Here we report on the characterization of a bioanalytical method to quantify DON in tissue samples involving DON derivatization with 3 N HCl in butanol. The derivatized product is lipophilic and stable. Detection of this analyte by mass spectrometry is fast and specific and can be used to quantify DON in plasma and brain tissue with a limit of detection at the low nanomolar level.

Original languageEnglish (US)
Pages (from-to)28-34
Number of pages7
JournalAnalytical Biochemistry
Volume474
DOIs
StatePublished - Apr 1 2015

Fingerprint

Diazooxonorleucine
Norleucine
Liquid chromatography
Liquid Chromatography
Mass spectrometry
Brain
Mass Spectrometry
Plasmas
Glutamine
Neurodegenerative diseases
Neurodegenerative Diseases
Metabolism
Glutaminase
Asparaginase
Neoplasms
Butanols
Tissue
Enzymes
Bioassay
Synaptic Transmission

Keywords

  • 6-Diazo-5-oxo-l-norleucine
  • DON bioanalysis
  • DON derivatization
  • Glutamine

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology
  • Cell Biology

Cite this

Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry. / Alt, Jesse; Potter, Michelle C.; Rojas, Camilo; Slusher, Barbara.

In: Analytical Biochemistry, Vol. 474, 01.04.2015, p. 28-34.

Research output: Contribution to journalArticle

@article{416d1d090f6e4a51b3ca9b8ea9168567,
title = "Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry",
abstract = "Glutamine is an abundant amino acid that plays pivotal roles in cell growth, cell metabolism, and neurotransmission. Dysregulation of glutamine-using pathways has been associated with pathological conditions such as cancer and neurodegenerative diseases. 6-Diazo-5-oxo-l-norleucine (DON) is a reactive glutamine analog that inhibits enzymes affecting glutamine metabolism such as glutaminase, 2-N-amidotransferase, l-asparaginase, and several enzymes involved in pyrimidine and purine de novo synthesis. As a result, DON is actively used in preclinical models of cancer and neurodegenerative disease. Moreover, there have been several clinical trials using DON to treat a variety of cancers. Considerations of dose and exposure are especially important with DON treatment due to its narrow therapeutic window and significant side effects. Consequently, a robust quantification bioassay is of interest. DON is a polar unstable molecule that has made quantification challenging. Here we report on the characterization of a bioanalytical method to quantify DON in tissue samples involving DON derivatization with 3 N HCl in butanol. The derivatized product is lipophilic and stable. Detection of this analyte by mass spectrometry is fast and specific and can be used to quantify DON in plasma and brain tissue with a limit of detection at the low nanomolar level.",
keywords = "6-Diazo-5-oxo-l-norleucine, DON bioanalysis, DON derivatization, Glutamine",
author = "Jesse Alt and Potter, {Michelle C.} and Camilo Rojas and Barbara Slusher",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.ab.2015.01.001",
language = "English (US)",
volume = "474",
pages = "28--34",
journal = "Analytical Biochemistry",
issn = "0003-2697",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry

AU - Alt, Jesse

AU - Potter, Michelle C.

AU - Rojas, Camilo

AU - Slusher, Barbara

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Glutamine is an abundant amino acid that plays pivotal roles in cell growth, cell metabolism, and neurotransmission. Dysregulation of glutamine-using pathways has been associated with pathological conditions such as cancer and neurodegenerative diseases. 6-Diazo-5-oxo-l-norleucine (DON) is a reactive glutamine analog that inhibits enzymes affecting glutamine metabolism such as glutaminase, 2-N-amidotransferase, l-asparaginase, and several enzymes involved in pyrimidine and purine de novo synthesis. As a result, DON is actively used in preclinical models of cancer and neurodegenerative disease. Moreover, there have been several clinical trials using DON to treat a variety of cancers. Considerations of dose and exposure are especially important with DON treatment due to its narrow therapeutic window and significant side effects. Consequently, a robust quantification bioassay is of interest. DON is a polar unstable molecule that has made quantification challenging. Here we report on the characterization of a bioanalytical method to quantify DON in tissue samples involving DON derivatization with 3 N HCl in butanol. The derivatized product is lipophilic and stable. Detection of this analyte by mass spectrometry is fast and specific and can be used to quantify DON in plasma and brain tissue with a limit of detection at the low nanomolar level.

AB - Glutamine is an abundant amino acid that plays pivotal roles in cell growth, cell metabolism, and neurotransmission. Dysregulation of glutamine-using pathways has been associated with pathological conditions such as cancer and neurodegenerative diseases. 6-Diazo-5-oxo-l-norleucine (DON) is a reactive glutamine analog that inhibits enzymes affecting glutamine metabolism such as glutaminase, 2-N-amidotransferase, l-asparaginase, and several enzymes involved in pyrimidine and purine de novo synthesis. As a result, DON is actively used in preclinical models of cancer and neurodegenerative disease. Moreover, there have been several clinical trials using DON to treat a variety of cancers. Considerations of dose and exposure are especially important with DON treatment due to its narrow therapeutic window and significant side effects. Consequently, a robust quantification bioassay is of interest. DON is a polar unstable molecule that has made quantification challenging. Here we report on the characterization of a bioanalytical method to quantify DON in tissue samples involving DON derivatization with 3 N HCl in butanol. The derivatized product is lipophilic and stable. Detection of this analyte by mass spectrometry is fast and specific and can be used to quantify DON in plasma and brain tissue with a limit of detection at the low nanomolar level.

KW - 6-Diazo-5-oxo-l-norleucine

KW - DON bioanalysis

KW - DON derivatization

KW - Glutamine

UR - http://www.scopus.com/inward/record.url?scp=84923323462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923323462&partnerID=8YFLogxK

U2 - 10.1016/j.ab.2015.01.001

DO - 10.1016/j.ab.2015.01.001

M3 - Article

C2 - 25584882

AN - SCOPUS:84923323462

VL - 474

SP - 28

EP - 34

JO - Analytical Biochemistry

JF - Analytical Biochemistry

SN - 0003-2697

ER -